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ABSTRACT 
Hypertension is the most common attributable risk factor for stroke and myocardial infarction, 
leading to death when inappropriately treated. Despite the wide pharmacological available selection, 
blood pressure remains uncontrolled in a significant proportion of patients. Resistant hypertension is 
an increasingly common clinical condition, defined by blood pressure ≥140/90 mmHg (or ≥130/80 
mmHg in diabetes or renal Insufficiency) regardless concurrent use of 3 or more antihypertensive 
drugs from different classes, including one diuretic, all at the optimal doses.  
As patients with hypertension are at elevated risk for cardiovascular morbidity and mortality, this 
review summarizes the available data, based on bibliographic research using PubMed’s data base, of 
new interventional approaches taking into account renal sympathetic activation’s role in 
hypertension pathogenesis.  
Renal Sympathetic Denervation is a novel catheter percutaneous procedure based on a therapeutic 
old concept which intends to ablate the nerves in order to interrupt the central nervous system and 
kidneys’ bidirectional connection. So far, trials have demonstrated convincing and safe blood 
pressure-lowering effects in majority of treated patients. Moreover, potential additional benefits on 
hypertension’s comorbidities, such as left ventricular hypertrophy and renal impairment, have been 
identified. Although this current evidence is mainly based on ablation through radiofrequency 
energy, several second-generation catheters have been developed aiming at safety and efficacy 
improvement.  
Therefore, renal sympathetic denervation appears as a future potential hypertension treatment 
option, despite being already conducted, under severe controlled conditions, in some countries.  
 
KEYWORDS 
Blood pressure; Radiofrequency ablation; Resistant Hypertension; Renal Sympathetic Denervation; 
Sympathetic nervous system activity   
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RESUMO 
A Hipertensão arterial é um dos principais fatores de risco para Acidente Vascular Cerebral e Enfarte 
do Miocárdio, resultando em morte quando não tratada. Apesar da vasta variabilidade 
farmacológica, a pressão arterial permanece incontrolada numa significativa percentagem de 
doentes. A Hipertensão resistente é uma situação clínica cada vez mais frequente, definida como 
pressão arterial ≥140/90 mmHg (ou ≥130/80 mmHg em caso de Diabetes ou Insuficiência Renal) 
apesar do uso concomitante de pelo menos 3 anti-hipertensivos de diferentes classes, incluindo um 
diurético, todos em doses adequadas. 
Visto que os doentes hipertensos apresentam um risco elevado de morbilidade e mortalidade 
cardiovasculares, esta revisão reúne a informação disponível, com base em pesquisa bibliográfica 
através da PubMed, de novas intervenções baseadas na influência do sistema simpático renal na 
patogénese da Hipertensão. 
A Desnervação Renal é um novo procedimento percutâneo fundamentado pelo antigo conceito 
terapêutico de ablação que interrompe a conexão bidirecional entre o sistema nervoso central e os 
rins. Até ao momento, os estudos têm demonstrado efeitos significativos e seguros na diminuição da 
pressão arterial na maioria dos indivíduos tratados. Para além disso, potenciais efeitos adicionais nas 
co-morbilidades da Hipertensão, como a Hipertrofia Ventricular Esquerda ou Disfunção Renal, têm 
sido detetados. Apesar da atual evidência ser baseada sobretudo na ablação por radiofrequência, 
vários cateteres têm sido desenvolvidos com o objetivo de melhorar a eficácia e segurança do 
procedimento. 
Assim, a Desnervação Renal apresenta-se como uma potencial futura opção para o tratamento da 
Hipertensão, apesar de já ser utilizada em alguns países, em situações muito específicas. 
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INTRODUCTION 
Hypertension (HT) is a growing worldwide public health problem with an overall prevalence around 
30-45% of the general population, with a steep increase with ageing attaining 65% in those over 60 
years of age.1 Since 2003 HT is defined as systolic blood pressure (SBP) ≥140 mmHg and/or diastolic 
blood pressure (DBP) ≥90 mmHg.2 It is recognized as the leading risk factor for cardiovascular and 
cerebrovascular disease, renal and visual impairment and death.3 Cardiovascular risk is linearly 
related to blood pressure (BP) levels, doubling with every 20/10 mmHg increase in SBP/DBP, 
beginning at 115/75 mmHg. Thereby, it is considered to be responsible for more than 7.5 million 
deaths annually in the world.4 A study conducted in 2003 showed that 42.1% of the Portuguese adult 
population aged 18-90 years had HT with a prevalence of approximately 79% in patients older than 
64 years. Among hypertensive subjects only 11.2% achieved adequate BP control.5 
HT can be primary (without apparent cause) or secondary to an identified etiology. The last, seldom 
diagnosed, is potentially curable or at least sensible to treatment with cardiovascular risk decrease.1 
The most common between these causes are obstructive sleep apnea, chronic renal disease 
(parenchymal and vascular) and primary hyperaldosteronism. Cushing’s syndrome, 
pheochromocytoma, hyperparathyroidism and aortic coarctation are less frequent causes.3  On the 
contrary, in most patients several factors contribute to disease’s development.6 Regardless the 
availability of several effective and safe antihypertensive treatment options, BP remains uncontrolled 
in a significant percentage of patients (approximately 50%).3,7,8 Table 1 discloses some patient 
characteristics associated with resistance to HT treatment. 
According to 2013 ESC/ESH recommendations and 2008 American Heart Association, resistant 
hypertension (RH) is defined as the inability to reach an effective BP control (<140/90 mmHg and 
<140/85 mmHg or <140mmHg  in case of diabetes and renal insufficiency, respectively) despite the 
association of at least 3 antihypertensive agents with different action mechanisms, one of these 
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being a diuretic, at the maximum tolerated dosage.1,3 Some authors also argue that patients whose 
BP is controlled with 4 or more medications are considered to have RH.9 
Pseudoresistant HT apparently includes treatment-resistant cases (poorly controlled BP) which are, 
however, attributed to other factors.10 Consequently, the RH concept rejects secondary forms, 
inefficient BP measurement technique, poor drug and lifestyle approach adherence and inadequate 
treatment strategy.11 Moreover, this clinical condition should only be established when the 
uncontrolled BP is confirmed to be permanent through 24h-ambulatory BP monitoring (24h-ABPM) 12 
with a mean threshold of SBP ≥130 and/or DBP ≥80 mmHg. This monitoring is essential to exclude 
pseudoresistance like white coat HT. RH has a multifactorial etiology and its exact prevalence 
remains unknown, varying from 5% to 30%.1,11 
In the past decades the Sympathetic Nervous System (SNS) has been recognized as a central player in 
the cardiovascular homeostasis13 and its enhanced activity has been established as a major 
contributor to chronic BP elevation.6 It is also well known that kidneys’ sympathetic innervation plays 
a major role in the pathogenesis of HT through modulation of renin’s secretion, glomerular filtration 
rate (GFR) and renal absorption of sodium. Based on constantly higher heart rates and absence of 
response to intensive diuretic treatment among patients with RH, some authors suggested that 
treatment failure may be due to neurologic mechanisms like sympathetic overactivity. This differs 
from the traditional assumption that RH is mainly due to persistent hypervolemia.10 
Therefore, considering the high prevalence of RH worldwide, the limited efficiency of 
pharmacological agents and the significant risk of accelerated cardiovascular mortality11, new 
therapeutic procedures targeting the SNS have been developed in order to correct or at least slow 
down the pathological mechanism. One of these new and refreshing interventional approaches is the 
Renal Sympathetic Denervation (RSD). This review outlines the impact of renal sympathetic activity 
on BP regulation, the recent evolution of RSD therapy on RH treatment and its future potential 
applications. 
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METHODS 
The present review was written based on bibliographic research using PubMed’s data base. The 
search was conducted based on MeSH terms using the following combinations: hypertension, blood 
pressure, autonomic denervation, catheter ablation, sympathectomy, sympathetic nervous system.  
 
 
HYPERTENSION TREATMENT 
Nowadays, essential HT therapy is based on lifestyle modifications and pharmacological agents. The 
former is based on both dietary adjustments with salt restriction (5-6 g per day is recommended) 
associated with high consumption of vegetables and fruits and regular exercise practice (at least 30 
minutes of moderate dynamic exercise on 5 to 7 days per week is recommended) leading to weight 
reduction (of BMI to 25 kg/m2 and of waist circumference to <102 cm in men and <88 cm in women 
is recommended, unless contraindicated). Moreover, smoking cessation and moderation of alcohol 
consumption (no more than 20-30 g and 10-20 g of ethanol per day in men and women, respectively) 
are essential for BP control.  
According to 2013 ESH/ESC Guidelines the major advantage of pharmacological therapy is BP-
lowering per se regardless the drug class of first line used, since all medications present similar 
effects and particular contraindications. Nevertheless, it must be taken into account both the 
adverse side effects and specific conditions in which some drugs have been proved to be more 
effective. The most used agents for the initiation and maintenance of therapy, contraindications and 
specific conditions to use each class are described on table 2. Combination therapy success has been 
attested not only in BP-lowering (possible synergism) but also in therapy compliance (single tablet) 
and side effects’ avoidance. Therefore, it is recommended initiation with combined therapy in 
patients with high cardiovascular risk or considerably high baseline BP.1 
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The new algorithm purposed by the Eighth Joint National Committee14 for the management of HT is 
exposed on figure 1. According to this Committee, BP thresholds for HT definition are maintained. 
However, as there are no proven beneficial effects of decreasing BP to levels lower than 140/90 
mmHg, the 2014 Guidelines recommend, with grade A level, BP <150/90 mmHg for the general 
population aged more than 60 years. 
 
 
ROLE OF SNS IN HYPERTENSIVE STATES 
The sympathetic nervous system (SNS) is a hallmark of primary HT implicated not only in the 
development, perpetuation and severity of the disease but also in the pathophysiological 
consequences associated (heart and end-stage renal disease) (figure 2).13,15 Nevertheless, only 
recently was its differential activation in the various organs established.16 
This differential autonomic cardiovascular modulation can be quantified through microneurography 
or regional spillover method. The former measures postganglionic sympathetic nerve firing in the 
subcutaneous nerves (skin and skeletal muscle vasculature), giving immediate information on the 
electrical transmission. The regional noradrenaline (NA) spillover method is considered nowadays the 
gold standard.13 This biochemical technique is a clinical index of organ-specific and overall SNS’s 
activity since NA efflux into the venous system is proportional to SNS’s firing rate. Consequently, 
during constant-rate infusion of radiolabeled NA (which takes into account NA uptake): regional NA 
spillover = [(CV - CA) + CAE] x PF, where CV and CA are the plasma concentrations of NA in regional 
venous and arterial plasma, respectively, E is the fractional extraction of radiolabeled NA in transit of 
blood through the organ, and PF is the organ plasma flow.17 
The cardiac baroreflex sensitivity reduction in HT has been recognized in various studies, confirming 
the SNS effect on the heart.18 There is also evidence of peripheral vasoconstriction related to SNS 
involvement. Additionally, measurement of kidney NA spillover revealed an increased activation of 
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sympathetic outflow with a mean elevation of 2 or 3 times the normal value.13,16 Therefore, the 
hyperkinetic circulation profile is early established in HT development with raised resting heart rate 
(HR) and cardiac output, increased peripheral and renovascular resistance and elevated plasmatic 
levels of NA, independent of disease severity stage.19 
The involvement of the renal SNS in the BP control is complex since it is simultaneously the receiver 
and originator of sympathetic signals by the efferent and afferent fibers, respectively, both located 
within the renal artery.20  
 
The efferent renal sympathetic nerves are regulated by central sympathetic outflow, vagal tone and 
renorenal reflexes. These fibers affect renal function not only by inducing antinatriuresis through 
elevation of renin secretion via the juxtaglomerular apparatus (β1-adrenoceptors) but also by 
enhancing sodium and water reabsorption through activation of the Na+/K+ adenosine 
triphosphatase in the renal tubular cells (α1B-adrenoceptors). On the other hand, they also decrease 
GFR by inducing direct renal vasoconstriction (α1A-adrenoceptors) which decreases renal blood flow. 
However, there seems to be a graded response depending on the effect of the sympathetic signal on 
adrenoceptors’ differential activation: low frequency stimulation only affects renin secretion whilst 
higher frequencies also influence sodium reabsorption and renal vascular tone.23 
The afferent renal sympathetic nerves are stimulated by chemoreceptors in renal interstitium and 
mechanoreceptors in the renal wall. The former are sensitive to variations in electrolyte 
concentration and plasma osmolality and renal ischemia. The mechanoreceptors are stimulated by 
signaling changes in hydrostatic renal pelvic pressure.20 The stimulation of these fibers modulates 
autonomic centers in the hypothalamus, the paraventricular nucleus, which increases (directly or 
through rostral ventrolateral medulla neurons’ activation) the sympathetic outflow to the kidney and 
other organs involved in the cardiovascular control, contributing to the neurogenic elevation of 
BP.13,15 Despite central sympathetic system’s predominant role, raised BP is also influenced by 
peripheral adrenergic abnormalities as inappropriate neuronal reuptake of NA or peripheral α-
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adrenoceptors’ downregulation.19 Consequently, through the influence on the regulation of overall 
sympathetic tone, afferent fibers have a predominant role in the genesis and maintenance of HT. 
Furthermore, these fibers are essential to preserve hydrolytic balance in case of unilateral excretion 
disorder since there is a direct communication with the contralateral kidney (renorenal reflex).7 
Subsequently, neurogenic primary HT is considered to be responsible for more than 50% of all cases 
of high BP.16 Although mechanisms of SNS overdrive are not completely understood, some 
hypotheses have been considered such as the impairment of volume-sensitive receptors or arterial 
chemoreceptors. Also, the contribution of humoral elements (insulin, angiotensin II) and the 
involvement of nutritional or behavioral features are suggested.19 
 
 
RENAL SYMPATHETIC DENERVATION (RSD) 
NEW TREATMENT FOR OLD DISEASE 
HISTORICAL BASIS FOR RSD 
SNS has been considered a possible therapeutic target in cases of RH since the early 20th century as 
its effect on vasoconstriction was already acknowledged. There were many surgical sympathectomy 
approaches with different removal extension.24 According to Gulati and White25, the radical lumbo-
dorsal splanchnicectomy was firstly developed in 1938 by Smithwick. Despite being extremely 
effective in BP control with reported cardiac size reduction, renal function improvement, decreased 
incidence of precordial pain and cerebrovascular events and mortality rate7, these procedures were 
associated with intolerable side effects like severe orthostatic hypotension, syncope, paradoxical 
excessive sweating, sphincter incontinence and erectile dysfunction. Moreover, the technique’s 
significant invasiveness associated with the development of effective and better tolerable oral 
sympathetic-blocking drugs led to its abandonment.26 
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Nonetheless, it was an undisputable proof-of-concept of SNS overdrive in RH, confirming BP control’s 
achievement through reduction in sympathetic tone. Besides, it revealed that adequate renal 
function is independent of intact renal SNS, confirmed by transplantation, since kidneys are still 
capable of maintaining electrolyte and volume homeostasis and adrenaline-mediated stress 
responses over time despite reduction in the sympathetic input.27 
 
 
RENAL RADIOFREQUENCY ABLATION (RFA) PROCEDURE – PIONEERING WORK 
Recently, RSD has been receiving additional interest as an HT therapeutic option not only because of 
sympathetic fibers’ activation role (in particular renal network) in disease’s progression and 
complications but also due to significant degree of SNS overdrive demonstrated in RH.19,28 The 
development of a new endovascular approach was based on cardiac arrhythmias efficient treatment 
with percutaneous radiofrequency ablation (RFA)24, aiming to avoid surgical denervation side effects 
and still achieve its success. Therefore, percutaneous renal RFA appears as a selective and minimally 
invasive procedure, with limited periprocedural risk and shorter recovery time.  
The catheter-based RSD therapy using radiofrequency was firstly outlined by Krum et al in an 
international Proof-of-principle study29 which included 50 patients with RH (table 3); 5 were excluded 
based on anatomical criteria. This group was followed-up during the trial and had comparable 
baseline patient characteristics (table 4). After renal artery angiography and heparin administration 
to achieve 250s activated clotting time, the “Symplicity” catheter was placed onto the distal renal 
artery wall via femoral artery. The catheter was connected to a radiofrequency generator which 
enabled energy delivery to endoluminal surface according to a predetermined algorithm and data on 
temperature, length of treatment and impedance, constantly monitored in order to prevent arterial 
injury. Radiofrequency energy, lower than that used for cardiac electrophysiological procedures, was 
delivered 4 to 6 times in each artery in a helical pattern lasting up to 2 minutes (figure 3). 
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The procedure was initially conducted in a 2-stage way (10 patients had contralateral artery ablation 
1 month later). As safety was established, it became a simultaneous bilateral procedure. Both 
treatment compliance and maintenance were emphasized to patients and physicians, respectively.   
In every visit after the procedure both office SBP and DBP revealed a significant decrease when 
compared to baseline (p<0.05). Although the extent of BP reduction is significantly different taking 
into account BP measurement method (table 4), office and ABPM decrease are strictly related. RFA 
efficiency was sustained even when medical treatment alterations were considered. Regardless the 
12-month promising outcomes, 6 patients’ BP decreased less than 10 mmHg (non-responders) which 
may point out to either ablation failure or SNS overdrive’s secondary role in some cases of RH. 
However, the mean decrease in renal NA spillover rate of 47% in 10 patients 15-30 days after the 
procedure associated with the significant reduction of total body NA spillover in 1 patient30 attested 
RSD effectiveness in kidney’s both efferent and afferent sympathetic drive reduction. 
No significant side effects were detected, both procedure-related renovascular damages (confirmed 
by 18 patients’ 14-30 days angiogram and 14 patients’ 6-month magnetic resonance angiogram) and 
renal function deterioration (GFR estimated in 25 patients). Only 2 surgical complications were 
identified which were immediately resolved: renal artery dissection through stenting and femoral 
artery aneurysm with antibiotics and analgesics. Also, the considerable amount of pain during the 
procedure (common pathway of sympathetic nerves and C pain fibers) led to a more aggressive 
control in the subsequent trials.31 
 
 
RECENT CLINICAL EVIDENCE  
 Symplicity system and trials  
Despite being the first evidence of RSD’s safety and efficiency, the small number of patients treated 
limited Proof-of-principle’s relevance. Therefore, investigators decided to spread the therapeutic 
approach to 153 patients, including the patients already treated and increase the follow-up period to 
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36-month (Symplicity HTN-1 Trial).32 After the first 12 months, patients were given the choice of a 24 
or 36 months follow-up period, 111 of whom agreed on the second period. The respective baseline 
data, BP variations and complications are reported on table 4. BP control (<140 mmHg) was 
significantly augmented through the follow-up period, contrarily to the decrease of patients with SBP 
>180 mmHg (from 30% at baseline to 5% at 36-month). Although re-innervation was hypothesized, 
BP-lowering persisted and even augmented at 36-month when compared with 12-month decrease, 
without HR’s significant alteration. One eventual explanation is the afferent renal fibers’ probable 
role on central sympathetic overdrive, changing the baroreflex to lower homeostatic regulation 
point.30,33 However, antihypertensive drug therapy’s influence remains undetermined since it could 
be changed after the 12th month. No significant differences were detected in BP-lowering considering 
age, renal function or diabetes status. Despite being overall well preserved, the 10 patients’ 24-
month GFR revealed a decrease of 16 mL/min/1.73m2.34 Nevertheless, according to Sadowski et al 
(2011) quoting Bakris and Williams, RSD has a renoprotective effect since GFR decline is lower than it 
would be expected considering baseline SBP. The 3 deaths that occurred (1 myocardial infarction, 1 
sudden death syndrome and 1 cardiac and respiratory arrest) were considered to be independent 
from the ablation procedure. No vascular alteration was detected at 6-month follow-up imaging 
(available in 81 patients)34 and stenosis rate was really low. Consequently, the results of the 
expanded-cohort were the first to demonstrate not only a sustained BP reduction but also a 
preserved safety and maintained renal function 3 years after the procedure. 
Nevertheless, Symplicity HTN-1 upholds Proof-of-study’s weaknesses since they lack a control group 
(risk of placebo and Hawthorne effect) and both the RH definition (without screening of HT etiology 
and no BP measurement method established) and exclusion criteria are inadequate. Moreover, 
follow-up numbers remain reduced and the antihypertensive regime adjustments and adherence 
were not taken into account. The unblinded analysis might also lead to observer bias. Besides, 
selection bias cannot be excluded.7,29,32,33,35 
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Meanwhile, in order to validate the outcomes obtained, the Symplicity HTN-236, an international 
randomized clinical trial, recruited 190 patients according to inclusion criteria (table 3). After 
recording medication intake and BP values for 2 weeks, 106 of these were randomly distributed in 
1:1 ratio to RSD or control groups, both continuing the previous antihypertensive treatment without 
adjustments except if medically required. 
At baseline, patients’ characteristics, mean BP and antihypertensive therapeutics between the two 
groups were identical. The primary endpoint was achieved in 49 of the treated patients (94.2%) and 
in 51 of the controls (94.4%), with a significantly different BP reduction between-group (p<0.05).  
However, once again these results differ from the 6-month 24h-ABPM (table 4). Six-month BP control 
(SBP <140 mmHg) was reached in 39% of RSD group compared to 6% of controls. Six-month SBP 
reduction ≥10 mmHg was also significantly different between-group. It is noteworthy to report the 
procedure’s complete inefficiency (no BP reduction) in 5 of the treated patients (10%). The 
antihypertensive treatment’s decrease was significantly different between groups: 20.4% in RSD and 
5.9% in control group. Contrarily, pharmacological intensification was not. Besides, there was no 
significant alteration in renal function in both groups during the follow-up period.  
Through 6-month imaging tests undertaken in 43 of the 49 patients no difference was detected in 
renal vascular anatomy. Although progression of a pre-existent atherosclerotic lesion was observed, 
it was placed away from the RSD ablation site. Bradycardia cases were successfully managed as well 
as the 5 minor periprocedure complications reported. Major complications during follow-up period 
were similar in both groups (table 4). Also, the occurrence of adverse effects was comparable 
between groups, without severe procedure or device-related complications in RSD group. 
 
After the 6-month follow-up period, control patients were offered the RSD procedure as long as they 
maintained SBP ≥160 mmHg.37 The crossover group (35 patients) had baseline demographic features 
and antihypertensive treatments comparable to the initial RSD group. This 12-month follow-up data 
exhibited not only persistence of significant BP reduction in the initial RSD group compared to 
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baseline (28/10 mmHg) but also an equivalent significant decrease in the crossover group: a variation 
of -24/-8 mmHg, comparable to the 6-month change in the initial interventional group (-32/-8 mmHg, 
p=0.15). Besides, therapy regimens’ modifications were not significantly different between the initial 
RSD and the crossover groups. GFR remained stable in both groups. Also, safety was confirmed 
through only 1 case of artery dissection, 3 hypertensive and 1 hypotensive episodes and no deaths. 
 
Symplicity HTN-2’s results, notwithstanding being on behalf of previous findings, are still 
questionable due to similar previous limitations: non-double blinded analysis, incomplete exclusion 
criteria (no secondary HT screening) and small sample size and follow-up period, which may mask the 
development of complications. Despite being a randomized trial, group baseline characteristics like 
sex, diabetes and coronary artery disease rates are different leading to a severity discrepancy into 
RSD group. Besides, since baseline 24h-ABPM was not measured, white-coat HT was not excluded. 
Although the included patients had to carry out a 2-week antihypertensive therapy, there was no 
systematic adherence assessment during follow-up.38-40 
 
RSD future trials need to respond to some of the questions brought up by past trials’ limitations. It is 
Symplicity HTN-3’s purpose41, a multicenter randomized single-blinded trial conducted in America, 
with wider inclusion and exclusion criteria in order to assess RSD’s both effectiveness and safety in 
true RH patients (table 5). Six-month both office-BP and 24h-ABPM are, respectively, primary and 
secondary efficiency outcomes, in order to clarify the differences observed in the previous trials. The 
6-month incidence of major adverse effects is the primary safety outcome.  
Following recruitment phase, in which were enrolled patients with SBP ≥160 mmHg while on stable 
treatment with 3 or more different drugs (including one diuretic) for no less than 2 weeks, there was 
the screening period with ABPM and therapy adherence registries for at least 2 weeks. Patients with 
sustained high SBP and mean 24h-ABPM ≥135 mmHg undertook selective renal angiography to verify 
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the accomplishment of anatomic criteria. 530 patients were posteriorly randomized in a 2:1 ratio to 
RSD or sham procedure, both continuing the previous medical treatment. 
As a blinded study, patients were unaware of randomization attribution with similar follow-up in 
both groups. Moreover, staff measuring BP was also blinded throughout all trial. Before 6-month 
evaluation, which includes renal artery duplex imaging, patients recorded ABPM and therapy intake 
for 2 weeks. Follow-up period is 3 years for both groups.  
 
The announcement made by Medtronic (symplicity system’s producer) on January the 9th 2014 
about Symplicity HTN-3’s results tempered RSD enthusiasm on RH treatment. Despite guaranteeing 
primary safety endpoint, the primary efficacy endpoint (a sustained SBP reduction at 6-month) was 
not accomplished. (http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-
newsArticle&id=1889335) According to Bakris, co-principal investigator, even though BP reduction 
was not statistically significant, the methodology used is far more rigorous than in previous trials. 
Therefore, despite believing European guidelines will be reformulated, he considers procedure’s 
dismissal ethically unacceptable. (http://www.medscape.com/viewarticle/819018) Besides, Dr. 
Marco Valgimigli, on behalf of the ESC, argues the importance of having the complete data since 
treatment’s efficacy is not determined by studies’ primary endpoint success. These concepts are also 
supported by Dr. Sanjay Kaul. Other investigators consider Symplicity HTN-3’s results as a possible 
failure's consequence of either procedure or Medtronic’s device. 
(http://www.medpagetoday.com/Cardiology/Hypertension/43726) However, only through the final 
data will definite conclusions be defined.  
 
 
 Others Renal Sympathetic Denervation trials  
24h-BP profile has been recognized as organ damage independent prognostic factor. Despite not 
established, autonomic dysfunction seems to be the probable underlying mechanism. Taking into 
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account RSD’s effect both on renal and total body sympathetic activity30, Zuern et al hypothesized a 
similar outcome regarding 24h-BP variability.42 Inclusion and exclusion criteria and methodology 
were comparable to Symplicity’s. Six months after the procedure, the selected patients (n=11) 
revealed both an office-SBP decrease equivalent to previous trials (-30.4 mmHg, p=0.007) and a 
significant 24h-BP variability reduction (systolic coefficient of variation: from 0.11 to 0.09, p=0.041; 
diastolic coefficient of variation: from 0.14 to 0.11, p=0.024), more pronounced than 24h-ABPM 
decline (SBP from 149 to 142 mmHg, p=0.086; DBP from 82 to 79 mmHg, p=0.167). 
 
SNS dysfunction is also a predictor of Chronic Kidney Disease’s (CKD) development and progression 
as afferent and efferent renal fibers contribute to the sympathetic overactivity vicious cycle. Hence, 
15 patients with concomitant RH and moderate to severe CKD underwent renal ablation.43 12-month 
results suggest not only RSD’s efficacy and safety since BP was significantly reduced (∆ office-BP=-
33/-19 mmHg) without procedure-related complications, but also maintenance of renal function 
(electrolyte and water homeostasis preserved; ∆GFR with p>0.05). Moreover, as all patients had 
baseline and follow-up 24h-ABPM, a significant effect on nocturnal BP was detected after only 3 
months (∆ABPM night-time=-14/-8 mmHg, p=0.03/0.02), through physiologic dipping pattern 
reestablishment (p=0.01). 
 
As BP reduction has enormous cardiovascular benefits (stroke, myocardial infarction, heart failure 
and death) RSD was recently performed in 20 cases of long-standing mild RH (even with 3 or more 
antihypertensive drugs, SBP=[140-160] mmHg) in order to determine procedure’s efficacy and 
safety.44 Six-month outcomes demonstrated office-SBP as well as mean systolic-ABPM significant 
decrease despite more modest than in Symplicity’s patients, respectively, -13.1 mmHg (p<0.01) and -
11.3 mmHg (p<0.01), associated with the absence of renal stenosis and preserved renal function 
(p=0.5). Therefore, further evidence is required to establish RSD as second-line therapy in mild RH. 
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In a multicenter national Portuguese registry, 78 patients were submitted to RSD, between July-2011 
and November-2012, using both Symplicity (n=75) and EnligHTN (n=3) catheters. Among the included 
patients mean office-BP was 176.5/94.7 mmHg, most having HT for more than 10 years. Despite the 
fact that 2 cases of significant stenosis at the final angiogram and 2 pseudoaneurysms were detected, 
RSD’s efficacy was proven by the 74% response rate in 23 patients with more than 6-month follow-
up.45 Already in September 2011 the procedure’s feasibility was confirmed by a Portuguese two-case 
report.46 
 
 
ABLATION CRITERIA  
Nowadays, based on clinical trial’s evidence, RSD via Symplicity catheter has been already approved 
in Australia47, Europe48 and Canada49 exclusively for RH treatment in patients with preserved renal 
function (GFR ≥45 mL/min/1.73m2). Therefore, only patients with raised office-SBP (≥160 mmHg or 
≥150 mmHg in type 2 diabetes patients) despite the combination of at least 3 antihypertensive drugs 
(including one diuretic) and without contributing factors, like increasing BP substances or 
inappropriate lifestyles, are recommended to this procedure. Secondary HT causes must be excluded 
as well as non-compliance to antihypertensive treatment. Moreover, confirmation of high BP 
through 24h-ABPM is required in order to exclude white-coat HT. Although medical therapy may be 
optimized with association of mineralocorticoid receptor antagonist, prolonged treatment with this 
drug is restricted due to its adverse effects. An imaging test of the renal system should be realized 
before the procedure since it is recommended in renal arteries ≥ 4mm in diameter and ≥ 20 mm in 
length before any major branch bifurcation (figure 4).  
As there is unsatisfactory clinical evidence, RSD is not recommended in cases of significant renal 
artery abnormalities (hemodynamically or anatomically), past renal interventions (angioplasty or 
stents), unstable clinical conditions (e.g. acute coronary event), pulmonary arterial HT, chronic 
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oxygen need, pregnancy, preeclampsia or children. Besides, this therapeutic approach should only be 
conducted in specialized centers fully equipped not only for diagnosis and procedure execution but 
also for complications management. It also requires infrastructure for a complete vigilance with 
constant follow-up assessments.50 
 
 
PROSPECTIVE DEVELOPMENTS 
Notwithstanding all the current questions, RSD through endovascular catheter has proved its 
influence in BP-lowering. Therefore, this therapeutic potential has led to an exponential 
development of new technological concepts (table 6) in order to exploit not only safety and 
efficiency with reduction of procedural time but also patient’s comfort through pain reduction.24,51 
Regarding RFA techniques, the most widely used is the Symplicity system. However, there are others 
systems using different catheters like EnligHTN multielectrode, Vessix Vascular V2 or OneShot 
already on trials that aim at reducing both BP and procedural time.21,52 RSD has been proved effective 
through ThermoCool, an off-the-shelf saline-irrigated RFA catheter, which is able to significantly 
decrease 24h-ABPM (-21/-11 mmHg, p=0.003/0.005) and SNS metabolites’ levels. As proved on 
cardiac electrophysiology ablation, this catheter is capable of minimizing the surface damage and 
increasing lesions’ depth since it actively cools the electrode.53 
Furthermore, this procedural improvement includes ultrasound as a more precise, quicker and less 
damaging ablative technique through both invasive and noninvasive procedures, also under 
development. Ultrasound energy consists in high-frequency sound waves being able to increase 
temperature at depth. The PARADISE catheter emits uniform circumferential ultrasound energy 
through the cylindrical transducer positioned inside the water balloon. This ultrasound ablation 
presented similar results to RFA’s, decreasing not only non-target tissue’s damage but also 
procedure’s time.54 
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Another strategy is tissue-directed microinfusion of neurotoxins, such as guanethidine or vincristine, 
into the vessel wall and perivascular area, leading to a chemical sympathectomy without the adverse 
side effects of systemic delivery.21,52  
However, all these approaches require long-term clinical data in order to correctly establish the most 
beneficial.24  
 
 
ADDITIONAL EFFECTS 
As SNS disorder is a systemic condition implicated in chronic diseases’ development, RSD is expected 
to have further physiologic benefits. Beyond HT, SNS dysfunction has been established in heart 
failure’s progression with β-blockers therapy as a survival prolonger.55 In a recent hypertensive heart 
disease trial56 46 patients underwent RSD while 18 attended as control group. The RSD group 
exhibited not only marked reduction of left ventricular (LV) mass (from 112.4 g/m2 at baseline to 94.9 
g/m2 at 6 months, p<0.001) but also significant improvement of both systolic and diastolic function at 
6-month echocardiography evaluation, compared with baseline and controls’ values (table 7). These 
results were associated with significant BP decrease. However, non-responders patients (BP 
reduction <10 mmHg) showed equally a significant decrease in LV mass and diastolic dysfunction 
which may emphasize RSD’s influence on LV hypertrophy despite the lack of BP response. 
An extension of Symplicity HTN-257, aiming at establishing RSD’s effect on physical activity with a 3:1 
randomization pattern, revealed BP reduction during exercise (from 226/104 mmHg at baseline to 
205/99 mmHg at 3 months; p<0.0001 for SBP, p=0.033 for DBP) without chronotropic function 
compromise (HR at peak exercise decreased 3 bpm, p=0.141). Also, BP after exercise (limited by 
symptoms’ development) and HR recovery improved in the 37 treated patients, -29/-8 mmHg 
(p<0.002) and +4 bpm (p=0.009), respectively. 
17 
 
Furthermore, RSD has been proved effective in HR reduction58 directly related to baseline HR values 
(p<0.05 when baseline HR >60 bpm). Six months after RSD, no correlation was established between 
its effect on HR or other electrocardiographic parameters and on BP (r=-0.102, p=0.369). On the 
contrary, PR prolongation, which confirms systemic sympathetic activity’s inhibition, is correlated 
with a more pronounced HR decrease. These breakthroughs are noteworthy since raised HR plays a 
major role in the pathogenesis of coronary disease, myocardial infarction, chronic heart failure and 
HT. 
Insulin’s role on SNS’s activation through direct central stimulation is already acknowledged. 
However, it has also been proved that SNS influences metabolic disarray.19 This potential effect on 
metabolic disorders was not only proved by fasting glucose, insulin and C-peptide levels’ significant 
reduction, -9.4 mg/dL (p=0.039), -11.6 μIU/mL (p=0.006) and -2.3 ng/mL (p=0.002) respectively, but 
also by the significant increase in insulin sensitivity (ISQUICKI=+0.04, p=0.001) in 37 patients 3 months 
after RSD, compared to unchangeable levels in control group.59 This data confirms the bidirectional 
relationship between SNS overactivity and insulin resistance. Nevertheless, RSD’s metabolic effects 
were not correlated with BP variation. Patients with obstructive sleep apnea and RH (n=10) revealed 
a metabolic control with improvement of hemoglobin A1C levels (from 6.1% to 5.6%, p<0.05) 
associated with BP (-34/-13 mmHg, p<0.01) and apnea-hypoapnea index reduction (from 16.3 to 4.5 
events per hour, p=0.059) 6 months after RSD.60 
Despite not being assertive, these indications are sufficient to promote future investigation of RSD’s 
additional effects. 
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CONCLUSION 
Gathering all the current evidence, RSD presents itself as a feasible, safe and clinically relevant 
procedure, able to significantly decrease BP levels in RH patients without important complications 
associated. Moreover, this technique has been proved effective in HT’s associated complications with 
potential cardiac function improvement, HR decrease and metabolic control enhancement. 
Since it is a recent interventional approach, most evidence assessing this procedure in humans comes 
from trials examining the efficacy and safety of the Symplicity Catheter System. Nevertheless, it has 
been submitted to great development with several endovascular catheters presenting different 
energy sources. 
However, enthusiasm for this possibly revolutionary procedure must be tempered since data is still 
restricted due to trial’s limitations which cast doubts about long-term durability or unpredictable 
effects development. Also, the discrepancy between office-BP and ABPM measurements raises the 
possibility of BP reduction being attributed to nonprocedural-related effects.  
Aside these apprehensions, RSD is already considered the last resort treatment in some countries 
exclusively for patients with RH who have exhausted all other available medical management 
options. 
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Fig. 1 - Algorithm for hypertension management. Adapted from James, Oparil and Carter (2013).14  β-blockers are not recommended for HT’s initial 
treatment since not only compared with the 4 recommended classes the results were similar in some studies but also stroke’s incidence was higher 
compared with ARB. *No diabetes or CKD. ǂ with or without diabetes. ACEI – angiotensin converting enzyme inhibitors; ARB – angiotensin receptor 
blockers; BP – blood pressure; CCB – calcium channel blockers; CKD – chronic kidney disease; DBP – diastolic blood pressure; SBP – systolic blood pressure.  
Adult aged ≥18 years 
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Fig.2 – Sympathetic nervous system role in Hypertension. Adapted from Bunte, Infante-Oliveira and 
Shishehbor (2013)21; Kanai and Krum (2013)22. GFR – glomerular filtration rate. 
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Fig.3 – The radiofrequency ablation procedure and simplicity cathether. Adapted from Kanai and 
Krum(2013)22. 
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Fig.4 – Recommended pathway to determine patients’ eligibility for Renal Sympathetic Denervation 
procedure. Adapted from Schlaich, Schmieder, Bakris et al(2013)50; Mahfoud, Luscher, Andersson et 
al(2013)48. ABPM – ambulatory blood pressure monitoring; BP – blood pressure; CKD – chronic 
kidney disease; DM – diabetes mellitus; GFR – glomerular filtration rate; HT- hypertension; NSAID’s – 
non-steroidal anti-inflammatory drugs; OSA – obstructive sleep apnea; RSD – renal sympathetic 
denervation; SBP – systolic blood pressure. 
  
30 
 
FIGURE LEGENDS 
 
Fig. 1 - Algorithm for hypertension management. Adapted from James, Oparil and Carter (2013).14  β-
blockers are not recommended for HT’s initial treatment since not only compared with the 4 
recommended classes the results were similar in some studies but also stroke’s incidence was higher 
compared with ARB. *No diabetes or CKD. ǂ with or without diabetes. ACEI – angiotensin converting 
enzyme inhibitors; ARB – angiotensin receptor blockers; BP – blood pressure; CCB – calcium channel 
blockers; CKD – chronic kidney disease; DBP – diastolic blood pressure; SBP – systolic blood pressure. 
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Table 1 – Patients characteristics associated with hypertension treatment-resistance 
RISK FACTORS 
 excessive sodium intake 
 excessive alcohol consumption 
 physical inactivity 
 female sex 
 African race 
 advanced age 
 higher baseline BP (specially systolic) 
 chronic renal disease 
 obesity 
 diabetes 
 presence of left ventricular hypertrophy 
 medications that increase BP or decrease antihypertensive agents effect 
 inadequate therapy 
 HT secondary causes 
Adapted from Calhoun et al (2008)
3
 and UpToDate (2013). BP – blood pressure; HT – hypertension. 
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Table 2 – Pharmacological treatment of Hypertension 
 ANTIHYPERTENSIVES † COMPELLING CONTRAINDICATIONS POSSIBLE CONTRAINDICATIONS CONDITIONS IN WHICH ARE PREFERRED 
A
C
E 
IN
H
IB
IT
O
R
S 
 
Captopril, Enalapril, Fosinopril, 
Imidapril, Lisinopril, Perindopril, 
Quinapril, Ramipril, Trandolapril, 
Zofenopril 
Pregnancy, bilateral renal artery 
stenosis angioneurotic oedema, 
hyperkalaemia,  
Women with child bearing 
potential 
LVH 
Microalbuminuria 
Renal dysfunction 
Previous MI 
HF 
Metabolic syndrome 
Diabetes mellitus 
Asymptomatic atherosclerosis ǂ  
Peripheral artery disease ǂ 
A
R
B
 
 
Telmisartan, Irbesartan, 
Candersartan, Losartan, 
Valsartan, Eprosartan 
Pregnancy, hyperkalaemia, 
bilateral renal artery stenosis 
Women with child bearing 
potential 
Β
-B
LO
C
K
ER
S 
 
Bisoprolol, Nebivolol, Carvedilol, 
Celiprolol, Atenolol, Metoprolol 
Asthma, A–V block (grade 2 or 3) Metabolic syndrome, glucose 
intolerance, athletes and 
physically active patients, COPD 
Previous MI 
Angina pectoris  
HF 
AF (ventricular rate control) 
Pregnancy 
C
A
LC
IU
M
 C
H
A
N
N
EL
 
B
LO
C
K
ER
S 
NONDIHYDROPYRIDINES 
Verapamil, Diltiazem 
A–V block (grade 2 or 3, 
trifascicular block), severe LV 
dysfunction, HF 
 LVH 
ISH (elderly) 
Angina pectoris  
Black population 
Pregnancy  
Peripheral artery disease 
Metabolic syndrome 
Asymptomatic atherosclerosis 
AF (ventricular rate control) * DIHYDROPYRIDINES 
Amlodipine,  
 Tachyarrhythmia 
HF 
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Table 2 – Pharmacological treatment of Hypertension (continuation) 
 ANTIHYPERTENSIVES † COMPELLING CONTRAINDICATIONS POSSIBLE CONTRAINDICATIONS CONDITIONS IN WHICH ARE PREFERRED 
D
IU
R
ET
IC
S 
THIAZIDE-TYPE 
Chlorthalidone, 
Indapamide, 
Hydrochlorothiazide 
Gout  HF 
ISH (elderly) 
Black population 
MINERALOCORTICOID RECEPTOR 
ANTAGONISTS 
Spironolactone, 
Eplenerone 
Acute or severe renal failure  
(eGFR <30 mL/min), hyperkalaemia 
Metabolic syndrome, glucose 
intolerance, pregnancy, 
hypercalcemia, hypokalaemia 
HF  
Adapted from ESC/ESH Guidelines (2013)
1
 and JNC8 Guidelines (2014)
14
.  ACE – angiotensin-converting enzyme; AF – atrial fibrillation; ARB – angiotensin receptor blockers; 
A-V – atrio-ventricular; COPD – chronic obstructive pulmonary disease; eGFR – estimated glomerular filtration rate; HF – heart failure; ISH – Isolated systolic hypertension; 
LV – left ventricular; LVH – left ventricular hypertrophy;  MI – myocardial infarction. † - Only some examples of several classes;  ǂ - not angiotensin receptor blockers; * - not 
dihydropyridines. 
  
34 
 
Table 3 – Proof-of-Principle, Symplicity HTN-1 and Symplicity HTN-2’s study characteristics 
 Type of study Inclusion Criteria Exclusion criteria Outcomes Follow-up  
P
R
O
O
F 
– 
O
F 
–P
R
IN
C
IP
LE
 Observational 
study 
 
▪SBP ≥ 160 mmHg with ≥ 3 
antihypertensive drugs (1 diuretic)  
▪confirmed intolerance to medications 
▪GFR ≥ 45 mL/min/1.73m
2 
 
▪≥ 18 years 
▪not pregnant 
▪secondary HT cause excluded 
▪type 1 diabetes 
▪hemodynamically significant valvular disease 
▪implanted pacemakers  
▪renovascular abnormalities (renal artery 
stenosis, previous renal stent or angioplasty, 
dual renal or polar arteries) 
▪on treatment with: clonidine, monoxidine, 
rilmenidine, warfarin 
Primary: 
▪BP reduction and procedural safety  
Secondary:  
▪NA release and renal function  
12 months 
 
SY
M
P
LI
C
IT
Y
 H
TN
-1
 Observational 
study 
 
Primary 
▪durability of BP-lowering effects 
▪ late adverse vascular or renal effects 
36 months 
SY
M
P
LI
C
IT
Y
 H
TN
-2
 
Randomized 
control trial  
(1:1 ratio) 
 
▪SBP ≥ 160 or ≥ 150 mmHg in type 2 
diabetics with ≥ 3 antihypertensive drugs 
▪2-week twice daily BP measurement and 
medication recording  
▪GFR ≥ 45 mL/min/1.73m
2
 
▪18-85 years  
 
▪type 1 diabetes 
▪substantial stenotic valvular heart disease 
▪renovascular abnormalities (major stenosis, 
previous intervention, precluding anatomy) 
▪contraindications to MRI 
▪history of MI, unstable angina or 
cerebrovascular accident in the last 6 months 
▪pregnancy 
Primary: 
▪ office-SBP difference between-group 
Secondary:  
▪procedural safety (acute and chronic) 
▪composite CV endpoint 
▪SBP reduction ≥ 10mmHg 
▪24h-ABPM and home-based BP change 
6 months 
ABPM – ambulatory blood pressure monitoring; BP – blood pressure; CV – cardiovascular; GFR – glomerular filtration rate; HT – Hypertension; MI – myocardial infarction; 
MRI – magnetic resonance imaging; NA – noradrenaline; SBP – systolic blood pressure.  
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Table 4 – Proof-of-study, Symplicity HTN-1 and Symplicity HTN-2’s results 
 Mean baseline values  Mean office-BP change  Non-responders*  ABPM change Complications 
P
R
O
O
F 
-O
F-
P
R
IN
C
IP
LE
 
RSD group (n=45) 
▪BP=177/101 mmHg 
▪GFR=81 mL/min/1.73m
2
 
▪4.7 antihypertensive drugs 
▪1
st
     
▪3
rd
    
▪6
th
   
▪9
th
    
▪12
th
 
-14/-10 (n=41) 
-21/-10 (n=39) 
-22/-11 (n=26) 
-24/-11 (n=20) 
-27/-17 (n=9) 
13% (6 patients) ▪ -11 mmHg (9 responders) 
▪ 10 mmHg (3 non-
responders)  
ǂ 
▪1 renal artery dissection (not procedure related) 
▪1 femoral pseudoaneurysm 
Control group (n=5) 
▪BP=173/98 mmHg 
▪GFR=95 mL/min/1.73m
2
 
▪4.6 antihypertensive drugs 
▪1
st
    
▪3
rd
  
▪6
th
   
▪9
th
    
+3/-2      (n=5) 
+2/+3     (n=5) 
+14/+9   (n=5) 
+26/+17 (n=2) 
   
SY
M
P
LI
C
IT
Y
  H
TN
-1
 
▪BP=175/98 mmHg 
▪GFR=85 mL/min/1.73m
2
 
▪5.1 antihypertensive drugs 
▪1
st
     
▪6
th
     
▪12
th
   
▪24
th 
▪36
th
 
-19/-9 (n=141) 
-22/-10 (n=144) 
-27/-14 (n=132) 
-29/-14 (n=105) 
-32/-14 (n=88) 
7% (6 patients)  ▪8 operative bradycardia 
▪1 renal artery dissection (not procedure related) 
▪3 femoral pseudoaneurysms 
▪renal stenosis: 2 progressions of pre-existing 
stenosis; 2 new cases (1 of 80%  needed stent) 
▪2 hypotensive events (unrelated to RSD); 2 
orthostatic hypotension episodes (same patient); 
13 hypertensive episodes; 1 acute tubular necrosis 
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Table 4 – Proof-of-study, Symplicity HTN-1 and Symplicity HTN-2’s results (continuation) 
 Mean baseline values  Mean office-BP change  Non-responders*  ABPM change Complications 
SY
M
P
LI
C
IT
Y
 H
TN
-2
 
RSD group (n=52) 
▪BP=178/96 mmHg 
▪GFR=77 mL/min/1.73m
2
 
▪5.2 antihypertensive drugs 
▪1
st
     
▪3
rd
    
▪6
th
   
 
-20/-7    (n=52) 
-24/.8     
-32/-12  (n=49) 
16.3% (8 patients) ▪ -11/-7 mmHg  
(20 patients) 
▪7 operative bradycardia;  
▪periprocedural (1 of each): hypotension, back 
pain, idiopathic paresthesia, urinary infection, 
femoral pseudoaneurysm 
▪progression of pre-existing stenosis  
▪5 HE (3 RSD + 2 control); 3 TIA (1 RSD + 2 control); 
2 anginas (1 in each group) 
Control group (n=54) 
▪BP=178/97 mmHg 
▪GFR=86 mL/min/1.73m
2
 
▪5.3 antihypertensive drugs 
▪1
st
     
▪3
rd
    
▪6
th
   
 
0/0    (n=54) 
-4/-2 
+1/0  (n=51) 
64.7% (33 patients) ▪ -3/-1 mmHg  
(25 patients) 
ABPM – ambulatory blood pressure monitoring; BP – blood pressure;  GFR – glomerular filtration rate; HE – hypertensive emergencies; RSD – renal sympathetic 
denervation; TIA – transient ischemic attack. * Non-responders: minimal systolic blood pressure reduction (< 10 mmHg); ǂ: patients with ABPM at baseline and at follow-up 
longer than 30 days after procedure. 
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Table 5 – Symplicity HTN-3  
INCLUSION CRITERIA  EXCLUSION CRITERIA EFFECTIVENESS ENDPOINTS SAFETY ENDPOINTS 
▪18-80 years 
▪office-SBP ≥160 mmHg 
(initial and confirmatory 
screening) 
▪stable medication 
regimen for at least 2 
weeks before initial 
screening and no 
changes planned for 6 
months 
▪written informed 
consent 
▪renovascular ineligibilities (diameter <4mm or length <20mm; multiple 
renal arteries; stenosis>50% or aneurysm; previous interventions) 
▪GFR <45 mL/min/1.73m
2
 
▪average ABPM <135 mmHg 
▪pregnancy, nursing  
▪chronic oxygen support or mechanical ventilation beyond night 
▪primary pulmonary HT, type 1 DM, pheochromocytoma, cushing’s disease, 
hyperthyroidism, hyperparathyroidism, coarctation of aorta, severe cardiac 
valve stenosis 
▪MI, unstable angina, syncope or cerebrovascular accident (prior 6 months) 
▪planned surgery or CV intervention in the next 6 months 
▪history of dependency, inability to comprehend instructions, unable to 
comply with trial’s requirements 
Primary 
▪office-SBP change 
 
Secondary 
▪average 24h-ABPM change 
▪incidence of: SBP reduction 
≥10, 15, 20 mmHg; SBP 
control (<140 or 130 mmHg 
in DM and RD); medication 
changes; home-BP change 
▪12, 18, 24 and 36-month BP 
change 
Primary 
▪major adverse events (MAE) 
incidence (composite of many 
events) 
▪new renal artery stenosis >70% 
(6-month angiography) 
 
Secondary: 
▪each component of MAE 
▪chronic safety 
▪change in renal function 
ABPM – ambulatory blood pressure monitoring; CV – cardiovascular; DM – Diabetes Mellitus; GFR – glomerular filtration rate; HT – Hypertension; MI – myocardial 
infarction; RD – renal disease; SBP – systolic blood pressure. 
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Table 6 – Overview of Renal Denervation systems 
PRODUCT NAME AND SPONSOR DESIGN OPERATING MODE ? CLINICAL TRIAL   
RADIOFREQUENCY ABLATION 
Symplicity catheter 
Medtronic Inc. 
Single-electrode  catheter Multiple rotations through spiral 
pattern 
Symplicity HTN 1-3; Renal Nerve 
Ablation in CKD patients; RDN  in 
patients with RH and OSA 
 
EnligHTN catheter 
St. Jude Inc. 
Multi-electrode catheter Simultaneous energy delivery to 4 
sites along arterial surface  
ARSENAL  
Vessix V2 catheter 
Vessix Vascular Inc. 
Balloon-mounted catheter Low-pressure balloon with superficial 
bipolar electrodes 
REDUCE-HTN  
OneShot catheter 
Maya Medical Inc. 
Irrigated balloon-mounted 
catheter 
Energy delivery by spiral electrode 
with cooling irrigation holes 
RAPID  
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Table 6 – Overview of Renal Denervation systems (continuation) 
PRODUCT NAME AND SPONSOR DESIGN OPERATING MODE ? CLINICAL TRIAL   
RADIOFREQUENCY ABLATION 
ThermoCool cryoablative 
catheter † 
Biosense Webster Inc. 
Irrigated catheter Constant preset energy delivery with 
maintenance of lower temperatures 
SWAN HT; SAVE; RELIEF  
Chilli II cryoablative catheter † 
Boston Scientific Inc. 
Irrigated catheter  SAVE  
ULTRASONIC ABLATION 
PARADISE catheter 
ReCor Medical Inc. 
US balloon catheter Circumferential energy by inflatable 
balloon with cooled fluid flow 
REALISE  
TIVUS catheter 
Cardiosonic Ltd. 
US autoregulating balloon 
catheter 
High-intensity, non-focused, self-
regulating ablation 
ǂ  
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Table 6 – Overview of Renal Denervation systems (continuation) 
PRODUCT NAME AND SPONSOR DESIGN OPERATING MODE ? CLINICAL TRIAL   
ULTRASONIC ABLATION 
Kona medical US system 
Kona Medical Inc. 
Low intensity external US 
ablation catheter 
Non-invasive low-intensity focused 
energy with imaging modality 
ǂ  
TISSUE-DIRECTED PHARMACOLOGICAL ABLATION 
Bullfrog micro-infusion 
catheter 
Mercator MedSystems Inc. 
Microneedle-equipped 
balloon catheter 
Perivascular direct delivery of 
neurotoxins 
ǂ  
Adapted from Bunte, Oliveira-Infante and Shishehbor (2013).
21
 ARSENAL – Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patient trial; CKD – 
chronic kidney disease; HTN – Hypertension; OSA – obstructive sleep apnea; PARADISE – ReCor Percutaneous Renal Denervation System catheter; RAPID – Rapid Renal 
Sympathetic Denervation for Resistant Hypertension trial; RDN – Renal Denervation; REALISE – Renal Denervation by Ultrasound Transcatheter Emission trial; REDUCE-HTN 
– Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter; RELIEF – Renal Sympathetic Denervation for the 
Management of Chronic Hypertension trial; RH – resistant hypertension; SAVE – Impact of Renal Sympathetic Denervation on Chronic Hypertension study; SWAN HT – 
Renal Sympathetic Modification in Patients With Essential Hypertension study; SYMPLICITY HTN-1 – SYMPLICITY I: One-Year Results Following Sympathetic Renal 
Denervation in Refractory Hypertension trial; SYMPLICITY HTN-2 – Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension trial; SYMPLICITY 
HTN-3 – Renal Denervation in Patients With Uncontrolled Hypertension trial; TIVUS – therapeutic intravascular ultrasound; † - unknown mechanism; ǂ - under development 
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Table 7 – RSD’s effect on left ventricular hypertrophy and cardiac function 
  HEMODYNAMIC  LV HYPERTROPHY SYSTOLIC FUNCTION DIASTOLIC FUNCTION 
   SBP/DBP  
(mmHg) 
HRR 
(bpm) 
LV 
mass/BSA 
(g/m2) 
IV septum 
thickness 
(mm) 
LV end-
systolic 
volume (mL) 
LV ejection 
fraction (%) 
Mitral E-wave 
deceleration 
(ms) 
Isovolumic 
relaxation 
time (ms) 
Diastolic 
relaxation 
velocity * (cm/s) 
LV filling 
pressure 
ǂ 
LA size 
(mm) 
R
SD
 g
ro
u
p
 (
n
=4
8
) 
B
as
el
in
e
 180.7/95.8 66.5 112.4 14.1 32.8 63.1 227.2 109.1 8.1 9.9 45.2 
6
 m
o
n
th
 
152.9/87.0 
(p<0.001) 
60.9 94.9 
(p<0.001) 
12.5 
(p=0.009) 
25.6  
 
(p=0.001) 
70.1 
(p=0.001) 
185.2 
(p=0.013) 
85.6 
(p=0.006) 
9.9 
(p=0.001) 
7.4 
(p=0.001) 
42.5 
(p<0.001) 
C
o
n
tr
o
ls
 (
n
=1
8
) 
B
as
el
in
e
 184.5/98.2 66.3 114.8 14.2 31.1 64.3 236.0 119.4 6.6 10.9 43.7 
6
 m
o
n
th
 182.8/99.8 64.3 118.7 14.2 31.8 62.9 233.4 11.6 6.3 12.1 46.0 
p for 
trend † 
0.0396/0.041 0.047 0.004 0.032 0.015 0.048 0.008 <0.001 0.023 0.001 0.021 
Adapted from Brandt et al(2012)
56
. BSA – body surface area; DBP – diastolic blood pressure; HRR – heart rate at rest; IV – interventricular; LA – left atrium; LV – left 
ventricular; RSD – renal sympathetic denervation; SBP – systolic blood pressure.* of the lateral mitral annulus; ǂ ratio of mitral inflow velocity to annular relaxation 
velocity); † differential efficacy between RSD and control group. 
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ANEXOS 
 
Normas de publicação da Revista Portuguesa de Cardiologia  
A Revista Portuguesa de Cardiologia, órgão oficial da Sociedade Portuguesa de Cardiologia, é uma 
publicação científica internacional destinada ao estudo das doenças cardiovasculares. Publica artigos 
em português na sua edição em papel e em português e inglês na sua edição online, sobre todas as 
áreas da Medicina Cardiovascular. Se os artigos são publicados apenas em inglês, esta versão surgirá 
simultaneamente em papel e online. Inclui regularmente artigos originais sobre investigação clínica 
ou básica, revisões temáticas, casos clínicos, imagens em cardiologia, comentários editoriais e cartas 
ao editor. Para consultar as edições online deverá aceder através do link www.revportcardiol.org. 
Todos os artigos são avaliados antes de serem aceites para publicação por peritos designados pelos 
Editores (peer review). A submissão de um artigo à Revista Portuguesa de Cardiologia implica que 
este nunca tenha sido publicado e que não esteja a ser avaliado para publicação noutra revista.  
Os trabalhos submetidos para publicação são propriedade da Revista Portuguesa de Cardiologia e a 
sua reprodução total ou parcial deverá ser convenientemente autorizada. Todos os autores deverão 
enviar a Declaração de Originalidade, conferindo esses direitos à RPC, na altura em que os artigos são 
aceites para publicação. 
 
 
Envio de manuscritos 
Os manuscritos para a Revista Portuguesa de Cardiologia são enviados através do link 
http://www.ees.elsevier.com/repc. Para enviar um manuscrito, é apenas necessário aceder ao 
referido link e seguir todas as instruções que surgem.  
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Responsabilidades Éticas 
Os autores dos artigos aceitam a responsabilidade definida pelo Comité Internacional dos Editores 
das Revistas Médicas (consultar www.icmje.org). 
Os trabalhos submetidos para publicação na Revista Portuguesa de Cardiologia devem respeitar as 
recomendações internacionais sobre investigação clínica (Declaração de Helsínquia da Associação 
Médica Mundial, revista recentemente) e com animais de laboratório (Sociedade Americana de 
Fisiologia). Os estudos aleatorizados deverão seguir as normas CONSORT. 
 
 
Informação sobre autorizações 
A publicação de fotografias ou de dados dos doentes não devem identificar os mesmos. Em todos os 
casos, os autores devem apresentar o consentimento escrito por parte do doente que autorize a sua 
publicação, reprodução e divulgação em papel e na Revista Portuguesa de Cardiologia. Do mesmo 
modo os autores são responsáveis por obter as respetivas autorizações para reproduzir na Revista 
Portuguesa de Cardiologia todo o material (texto, tabelas ou figuras) previamente publicado. Estas 
autorizações devem ser solicitadas ao autor e à editora que publicou o referido material. 
 
 
Conflito de interesses 
Cada um dos autores deverá indicar no seu artigo se existe ou não qualquer tipo de Conflito de 
Interesses. 
 
 
Declaração de originalidade 
O autor deverá enviar uma declaração de originalidade. Ver anexo I 
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Proteção de dados 
Os dados de carácter pessoal que se solicitam vão ser tratados num ficheiro automatizado da 
Sociedade Portuguesa de Cardiologia (SPC) com a finalidade de gerir a publicação do seu artigo na 
Revista Portuguesa de Cardiologia (RPC). Salvo indique o contrário ao enviar o artigo, fica 
expressamente autorizado que os dados referentes ao seu nome, apelidos, local de trabalho e 
correio eletrónico sejam publicados na RPC, bem como no portal da SPC (www.spc.pt) e no portal 
online www.revportcardiol.org, com o intuito de dar a conhecer a autoria do artigo e de possibilitar 
que os leitores possam comunicar com os autores. 
 
 
INSTRUÇÕES AOS AUTORES 
Todos os manuscritos deverão ser apresentados de acordo com as normas de publicação. Pressupõe-
se que o primeiro autor é o responsável pelo cumprimento das normas e que os restantes autores 
conhecem, participam e estão de acordo com o conteúdo do manuscrito. 
 
 
NOTA IMPORTANTE! Para que se possa iniciar o processo de avaliação, o documento com o corpo do 
artigo deverá incluir todos os elementos que fazem parte do artigo: Títulos em português e em 
inglês; autores; proveniência; palavras-chave e keywords; Resumos em português e em inglês; Corpo 
do artigo, incluindo as tabelas; bibliografia; legendas das figuras e das tabelas.  
 
1. Artigos Originais 
Apresentação do documento: 
• Com espaço duplo, margens de 2,5 cm e páginas numeradas. 
• Não deverão exceder 5.000 palavras, contadas desde a primeira à última página, excluindo as 
tabelas. 
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• Consta de dois documentos: primeira página e manuscrito 
• O manuscrito deve seguir sempre a mesma ordem: a) resumo estruturado em português e 
palavras-chave; b) resumo estruturado em inglês e palavras-chave; c) quadro de abreviaturas em 
português e em inglês; d) texto; e) bibliografia; f) legendas das figuras; g) tabelas (opcional) e h) 
figuras (opcional)- 
 
 
Primeira página 
Título completo (menos de 150 caracteres) em português e em inglês. 
Nome e apelido dos autores pela ordem seguinte: nome próprio, seguido do apelido (pode conter 
dois nomes) 
Proveniência (Serviço, Instituição, cidade, país) e financiamento caso haja. 
Endereço completo do autor a quem deve ser dirigida a correspondência, fax e endereço eletrónico. 
Faz-se referência ao número total de palavras do manuscrito (excluindo as tabelas). 
 
 
Resumo estruturado 
O resumo, com um máximo de 250 palavras, está dividido em quatro partes: a) Introdução e 
objetivos; b) Métodos; c) Resultados e d) Conclusões. Deverá ser elucidativo e não inclui referências 
bibliográficas nem abreviaturas (exceto as referentes a unidades de medida). 
Inclui no final três a dez palavras-chave em português e em inglês. Deverão ser preferencialmente 
selecionadas a partir da lista publicada na Revista Portuguesa de Cardiologia, oriundas do Medical 
Subject Headings (MeSH) da National Libray of Medicine, disponível em: 
www.nlm.nihgov/mesh/meshhome.html. 
O resumo e as palavras-chave em inglês devem ser apresentados da mesma forma. 
 
46 
 
Texto 
Deverá conter as seguintes partes devidamente assinaladas: a) Introdução; b) Métodos; c) 
Resultados; d) Discussão e e) Conclusões. Poderá utilizar subdivisões adequadamente para organizar 
cada uma das secções. 
As abreviaturas das unidades de medida são as recomendadas pela RPC (ver Anexo II). 
Os agradecimentos situam-se no final do texto. 
 
 
Bibliografia 
As referências bibliográficas deverão ser citadas por ordem numérica no formato ‘superscript’, de 
acordo com a ordem de entrada no texto. As referências bibliográficas não incluem comunicações 
pessoais, manuscritos ou qualquer dado não publicado. Todavia podem estar incluídos, entre 
parêntesis, ao longo do texto. São citados abstracts com menos de dois anos de publicação, 
identificando-os com [abstract] colocado depois do título. As revistas médicas são referenciadas com 
as abreviaturas utilizadas pelo Index Medicus: List of Journals Indexed, tal como se publicam no 
número de Janeiro de cada ano. Disponível em: 
http://www.ncbi.nlm.nih.gov/entrez/citmatch_help.html#JournalLists. O estilo e a pontuação das 
referências deverão seguir o modelo Vancouver 3. 
Revista médica: Lista de todos os autores. Se o número de autores for superior a três, incluem-se 
os três primeiros, seguidos da abreviatura latina et al. Exemplo:  
17. Sousa PJ, Gonçalves PA, Marques H et al. Radiação na AngioTC cardíaca; preditores de maior 
dose utilizada e sua redução ao longo do tempo. Rev Port cardiol, 2010; 29:1655-65 
Capítulo em livro: Autores, título do capítulo, editores, título do livro, cidade, editora e páginas. 
Exemplo:  
23. Nabel EG, Nabel GJ. Gene therapy for cardiovascular disease. En: Haber E, editor. Molecular 
cardiovascular medicine. New York: Scientific American 1995. P79-96. 
47 
 
Livro: Cite as páginas específicas. Exemplo:  
30. Cohn PF. Silent myocardial ischemia and infarction. 3rd ed. New York: Mansel Dekker; 1993. P. 
33. 
Material electrónico: Artigo de revista em formato eletrónico. Exemplo:  
Abood S. Quality improvement initiative in nursing homes: the ANA acts it an advisory role. Am J 
Nurs. [serie na internet.] 2002 Jun citado 12 Ago 2002:102(6): [aprox. 3] p. Disponível em: 
http://www.nursingworld.org/AJN/2002/june/Wawatch.htm 
A Bibliografia será enviada como texto regular, nunca como nota de rodapé. Não se aceitam códigos 
específicos dos programas de gestão bibliográfica. 
 
Figuras 
As figuras correspondentes a gráficos e desenhos são enviadas no formato TIFF ou JPEG de 
preferência, com uma resolução nunca inferior a 300 dpi e utilizando o negro para linhas e texto. São 
alvo de numeração árabe de acordo com a ordem de entrada no texto. 
• A grafia, símbolos, letras, etc, deverão ser enviados num tamanho que, ao ser reduzido, os 
mantenha claramente legíveis. Os detalhes especiais deverão ser assinalados com setas 
contrastantes com a figura. 
• As legendas das figuras devem ser incluídas numa folha aparte. No final devem ser identificadas as 
abreviaturas empregues por ordem alfabética. 
• As figuras não podem incluir dados que dêem a conhecer a proveniência do trabalho ou a 
identidade do paciente. As fotografias das pessoas devem ser feitas de maneira que estas não sejam 
identificadas ou incluir-se-á o consentimento por parte da pessoa fotografada. 
 
Tabelas 
São identificadas com numeração árabe de acordo com a ordem de entrada no texto. Cada tabela 
será escrita a espaço duplo numa folha aparte. 
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• Incluem um título na parte superior e na parte inferior são referidas as abreviaturas por ordem 
alfabética. 
• O seu conteúdo é auto-explicativo e os dados que incluem não figuram no texto nem nas figuras. 
 
 
2. Artigos de Revisão 
Nº máximo de palavras do artigo sem contar com o resumo e quadros- 5.000 
Nº máximo de palavras do Resumo - 250 
Nº máximo de Figuras - 10 
Nº máximo de quadros - 10 
Nº máximo de ref. bibliográficas - 100 
 
 
3. Cartas ao Editor 
Devem ser enviadas sob esta rubrica e referem-se a artigos publicados na Revista. Serão somente 
consideradas as cartas recebidas no prazo de oito semanas após a publicação do artigo em questão. 
• Com espaço duplo, com margens de 2,5 cm. 
• O título (em português e em inglês), os autores (máximo quatro), proveniência, endereço e figuras 
devem ser especificados de acordo com as normas anteriormente referidas para os artigos originais. 
• Não podem exceder as 800 palavras. 
• Podem incluir um número máximo de duas figuras. As tabelas estão excluídas. 
 
 
4. Casos Clínicos 
Devem ser enviados sob esta rubrica. 
• A espaço duplo com margens de 2,5 cm. 
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• O título (em português e em inglês) não deve exceder 10 palavras 
Os autores (máximo oito) proveniência, endereço e figuras serão especificados de acordo com as 
normas anteriormente referidas para os artigos originais. O texto explicativo não pode exceder 3.000 
palavras e contem informação de maior relevância. Todos os símbolos que possam constar nas 
imagens serão adequadamente explicados no texto. Contêm um número máximo de 4 figuras e pode 
ser enviado material suplementar, como por exemplo vídeoclips. 
 
 
5. Imagens em Cardiologia 
• A espaço duplo com margens de 2,5 cm. 
• O título (em português e em inglês) não deve exceder oito palavras 
• Os autores (máximo seis), proveniência, endereço e figuras serão especificados de acordo com as 
normas anteriormente referidas para os artigos originais. 
• O texto explicativo não pode exceder as 250 palavras e contem informação de maior relevância, 
sem referências bibliográficas. Todos os símbolos que possam constar nas imagens serão adequada-
mente explicados no texto. 
• Contêm um número máximo de quatro figuras. 
Normas de publicação da revista portuguesa de cardiologia 
 
 
6. Material adicional na WEB 
A Revista Portuguesa de Cardiologia aceita o envio de material eletrónico adicional para apoiar e 
melhorar a apresentação da sua investigação científica. Contudo, unicamente se considerará para 
publicação o material eletrónico adicional diretamente relacionado com o conteúdo do artigo e a sua 
aceitação final dependerá do critério do Editor. O material adicional aceite não será traduzido e 
publicar-se-á eletronicamente no formato da sua receção. 
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Para assegurar que o material tenha o formato apropriado recomendamos o seguinte:  
 
 FORMATO EXTENSÃO DETALHES 
TEXTO Word .doc ou docx Tamanho máximo 300 Kb 
IMAGEM TIFF .tif Tamanho máximo 10 Mb 
AUDIO MP3 .mp3 Tamanho máximo 10 Mb 
VÍDEO WMV .wmv Tamanho máximo 30 Mb 
 
 
 
